Monkeypox Vaccine Development and Vaccination Strategies
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 183
Special Issue Editors
Interests: vaccinology; immune responses; monkeypox
Special Issue Information
Dear Colleagues,
Monkeypox is a zoonotic disease that was once endemic in west and central Africa, caused by the orthopoxvirus, monkeypox virus. However, recent cases have been confirmed in many nonendemic countries outside of Africa. The WHO declared the ongoing monkeypox outbreak to be a public health emergency of international concern on 23 July 2022. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets and via fomites such as towels and bedding. Strategies for prevention, such as the smallpox vaccine has been recommended in high-risk persons. Multiple medical countermeasures are stockpiled for orthopoxviruses, such as monkeypox. Two vaccines are currently available, JYNNEOSTM (live, replication-incompetent vaccinia virus) and ACAM2000® (live, replication-competent vaccinia virus). The development of vaccines against the monkeypox virus and different vaccination strategies are urgently needed. In this context, this Special Issue invites you to submit your research related to scientific advances in the field of monkeypox vaccine development and vaccination strategies.
Dr. Natalie Prow
Dr. Preethi Eldi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- monkeypox virus
- vaccine development
- vaccination strategies
